Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Large B-cell Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03583424
What this trial is testing

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+9 more
Ohio State University Comprehensive Cancer Center 19
Testing effectiveness (Phase 2)Ended earlyNCT05588440
What this trial is testing

A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Relapsed/Refractory Aggressive B-Cell Malignancies
Oncternal Therapeutics, Inc 9
Testing effectiveness (Phase 2)WithdrawnNCT03999658
What this trial is testing

STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Who this might be right for
Peripheral T Cell LymphomaDiffuse Large B Cell LymphomaBiliary Tract Cancer+1 more
Sorrento Therapeutics, Inc.
Testing effectiveness (Phase 2)Study completedNCT02600897
What this trial is testing

Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 114
Early research (Phase 1)Looking for participantsNCT05794958
What this trial is testing

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Who this might be right for
Non-Hodgkin LymphomaLarge B-cell Lymphoma
Stanford University 20
Not applicableApproved For MarketingNCT04300803
What this trial is testing

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Who this might be right for
DLBCL
MorphoSys AG
Testing effectiveness (Phase 2)UnknownNCT02851589
What this trial is testing

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma+3 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)Study completedNCT02950220
What this trial is testing

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular Lymphoma+16 more
Kami Maddocks 2
Early research (Phase 1)Looking for participantsNCT04545762
What this trial is testing

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Refractory Non-Hodgkin LymphomaBurkitt LymphomaMantle Cell Lymphoma+7 more
C. Babis Andreadis 36
Early research (Phase 1)Study completedNCT00083213
What this trial is testing

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Cancer
Regeneron Pharmaceuticals 25
Early research (Phase 1)Ended earlyNCT00004058
What this trial is testing

12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
University of Medicine and Dentistry of New Jersey
Early research (Phase 1)Study completedNCT00036946
What this trial is testing

VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
LymphomaUnspecified Adult Solid Tumor, Protocol Specific
Regeneron Pharmaceuticals
Large-scale testing (Phase 3)Looking for participantsNCT07570823
What this trial is testing

Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
DLBCL - Diffuse Large B Cell Lymphoma
Sinocelltech Ltd. 101
Early research (Phase 1)Study completedNCT01231919
What this trial is testing

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Leukemias of Ambiguous LineageAcute Myeloid Leukemia/Transient Myeloproliferative Disorder+48 more
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)UnknownNCT00002481
What this trial is testing

Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
St. Luke's Medical Center
Testing effectiveness (Phase 2)Study completedNCT02401048
What this trial is testing

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Who this might be right for
Diffuse Large B-Cell LymphomaFollicular Lymphoma
Pharmacyclics LLC. 61
Early research (Phase 1)Temporarily pausedNCT00077493
What this trial is testing

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
MedImmune LLC 95
Very early researchLooking for participantsNCT04512716
What this trial is testing

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Who this might be right for
B-ALLDLBCLB ALL+8 more
Memorial Sloan Kettering Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT02445248
What this trial is testing

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Who this might be right for
Diffuse Large B-cell Lymphoma (DLBCL)
Novartis Pharmaceuticals 115
Early research (Phase 1)Looking for participantsNCT06980116
What this trial is testing

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Relapsed or Refractory B-cell MalignanciesChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Follicular Lymphoma (FL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 85
Next Page